MET and colorectal carcinoma: Both genomic and tissue‐based assays have been used clinically to predict a patient's likelihood of response to MET inhibition in CRC, but a lack of population‐based evidence to interpret the prognostic outcomes of aberrant c‐MET activity in CRC means there is little evidence to support their use [6, 13].